Full-Time

Sub-chapter Lead

Marketing Vault and Product Hub

Posted on 5/2/2026

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Indianapolis, IN, USA + 4 more

More locations: Bellheim, Germany | Pleasanton, CA, USA | Tucson, AZ, USA | Sant Cugat del Vallès, Barcelona, Spain

In Person

Category
Operations & Logistics (2)
,
Required Skills
Veeva
SAP Products
Requirements
  • Strong operational mindset with experience in Shared Services, Content Operations, or Product Lifecycle Management.
  • Experience with MarTech systems (Digital Asset Management, Veeva, etc.) and ERP systems (SAP).
  • Ability to manage process standardization, with a focus on continuous improvement, and drive efficiency in a high-volume environment.
  • Stakeholder management
  • Leadership in the context of geographically dispersed teams
Responsibilities
  • Marketing Vault Management: Create and Manage the "Marketing Vault" as a one-stop-shop for all marketing materials and product knowledge.
  • Ensure the library is AI-enabled to allow for hyper-personalization and modular content usage by affiliates.
  • Content Lab: Own the centralized service, provider, and process for content localization, including translation, for affiliates.
  • Product Hub Operations: Centralize transactional and administrative activities to support affiliates, such as creating customer-facing notifications (safety/marketing), SAP material maintenance, and phase-in/phase-out administration.
  • Process Standardization: Drive the standardization of additional product management processes across all affiliates to enable centralization and automation.
  • Content Compliance: Owner of the Promotional Content Approval Process (PCAP). You will work to improve and automate compliance checks to speed up time-to-market for marketing assets.
  • Efficiency Drivers: Continuously monitor the usage of the Marketing Vault and Product Hub, identifying opportunities to offload more administrative work from local marketers and local product managers to this central team.
  • People leadership: Build, inspire and lead the Marketing Vault and Product hub Team, across global sites. Provide clear vision and contribute to the overall chapter’s strategic direction.
  • Key stakeholder management, specifically with Global Marketing, Global Digital Marketing, Local Marketing, Regulatory & Quality teams, Commercial IT, Business Areas and Customer Areas.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • CE-marked pTau217 expands Alzheimer's testing beyond specialist memory clinics across Europe.
  • PathAI acquisition strengthens AI-driven pathology and companion diagnostics workflows in 2026.
  • CT-388 gives Roche a credible entry into the obesity market.

What critics are saying

  • Eli Lilly and Biogen/Eisai already dominate Alzheimer's testing and treatment pull-through.
  • Swiss franc strength and patent expirations are pressuring reported sales and cash flow.
  • Novo Nordisk and Eli Lilly set an extremely high bar for CT-388 performance.

What makes Roche unique

  • Roche unites diagnostics, medicines, and digital pathology under one commercial roof.
  • Founded in Basel in 1896, Roche built deep global clinical trust.
  • Elecsys runs on Roche cobas instruments, creating standardized testing across care settings.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Roche who can refer or advise you

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE